ACUTE TOXICITY OF A NEW BENZIMIDAZOLE DERIVATIVE WITH ANTITHROMBOGENIC PROPERTIES

封面

如何引用文章

全文:

详细

The paper presents the results of studying the toxicological profile of a new pharmaceutical substance RU891 with antithrombogenic properties. The minimum toxic dose (TDmin) for RU-891 by peroral administration is 230 mg/kg < TDmin ≤ 460 mg/kg. In experiments on the acute toxicity of the compound RU-891, the nature and severity of its damaging effect on the body of experimental animals were established and the safety of its action was evaluated. When studying the toxic effect of the test sample, the tolerated and toxic doses of RU-891 were determined, and the most sensitive organs and systems of the body were identified.

作者简介

A. Spasov

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health; Volgograd Medical Research Center, Laboratory of Experimental Pharmacology

编辑信件的主要联系方式.
Email: aspasov@mail.ru

Spasov Aleksandr Alekseyevich

 400131, Volgograd

俄罗斯联邦

A. Kucheryavenko

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health

Email: aidakucheryavenko@yandex.ru

Kucheryavenko Aida  Fatikhovna

 400131, Volgograd

俄罗斯联邦

D. Maltsev

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health;Volgograd Medical Research Center, Laboratory of Experimental Pharmacology

Email: maltsevdmitriy@rambler.ru

Maltsev Dmitriy Vasil’yevich

400131, Volgograd

俄罗斯联邦

М. Miroshnikov

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health

Email: mihailmiroshnikov@mail.ru

Miroshnikov Mikhail Vladimirovich

 400131, Volgograd

俄罗斯联邦

V. Sirotenko

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health

Email: sirotenko.viktor@yandex.ru

Sirotenko Viktor Sergeevich

 400131, Volgograd

俄罗斯联邦

К. Sultanova

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health

Email: sultanova.pharma@gmail.com

Sultanova Kira Timurovna

 400131, Volgograd

俄罗斯联邦

К. Gaidukova

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health

Email: ksenijagajjdukva@rambler.ru

Gaidukova Ksenia Andreevna

 400131, Volgograd

俄罗斯联邦

М. Skripka

Volgograd State Medical University, Department of Pharmacology and Bioinformatics, RF Ministry of Health

Email: rete.mirabile.renis@gmail.com

Skripka Maria Olegovna

 400131, Volgograd

俄罗斯联邦

参考

  1. Anisimova V.A., Spasov A.A., Ostrovskii O.V., Dudchenko G.P., Kosolapov V.A., Kucheryavenko A.F. et al. Synthesis and pharmacological activity of 3-aroyl- and 3-hetaroylimidazo[1,2-a] benzimidazoles. Pharmaceutical Chemistry Journal. - 2002. - Vol. 36.- No. 12.- pp. 637-642.
  2. Anisimova V.A., Kucheryavenko A.F., Spasov A.A. et al. Synthesis and biological activity of n-acylmethyl derivatives of 9h-2,3-dihydroimidazo- and 10h-2,3,4,10-tetrahydropyrimido[1,2-a] benzimidazoles and their reduction products. Pharmaceutical Chemistry Journal. - 2006. - Vol. 40. – No. 5.- pp. 261-267.
  3. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J. et al. Heart disease and stroke statistics (a report from the American Heart Association). Circulation. - 2016. – No. 133. - pp. 38–60.
  4. Spasov A.A., Nedogoda V.V., Konan K., Kucheryavenko A.F. Мechanism of reduction of platelet sensitivity to medicines in response to low-energy laser radiation of blood. Hematology and Transfusiology. - 2001. - Vol.46. – No. 2. - pp. 36-39 (in Russian).
  5. Bugaeva L.I., Kuzubova E.A., Bukatin M.V., Spasov A.A. Neurotoxicological properties of the drug «Bendazol». Vestnik VolgSMU. - 2012. - No. 2. - pp. 83-86 (in Russian).
  6. Golukhova E.Z., Ryabinina M.N. Modern aspects of antiplatelet therapy.Creative Cardiology. - 2013. - No. 1. - pp. 46-58 (in Russian).
  7. Kucheryavenko A.F., Anisimova V.A., Gaidukova K.A., Divaeva L.N., Spasov A.A. et al. Antiplatelet activity of a new bicyclic derivative of 2,3,4,5-tetrahydro[1,3]diazepino[1,2-a] benzimidazole. Experimental and Clinical Pharmacology. - 2016. - Vol. 79. - No. 5. - pp. 29-32 (in Russian).
  8. Kucheryavenko A.F., Spasov A.A., Petrov V.I. et al. Antiplatelet activity of a new benzimidazole derivative. Bulletin of Experimental Biology and Medicine. - 2013. - Vol. 156. - No. 12. - pp. 760- 762 (in Russian).
  9. Miroshnikov M.V. et al. The anxiolytic potential of a new series of diazepinobenzimidazole derivatives. Vestnik VolgSMU. - 2018. - Vol. 67. - No. 3. - p. 19 (in Russian).
  10. Spasov A.A., Kucheryavenko A.F., Kosolapov V.A., Anisimova V.A. Antithrombogenic activity of antioxidant compounds. Bulletin of Experimental Biology and Medicine. - 2013. - Vol. 155. - No. 6-pp. 740-742 (in Russian).
  11. Spasov A.A., Dudchenko G.P., Gavrilova E.S., Kucheryavenko A.F. et al. Diabenol - new antidiabetic substance with geobiological properties. Bulletin of the Volgograd Medical Academy. - 1997. - Vol. 52. - No. 3. - pp. 47-51 (in Russian).
  12. Spasov A.A., Kucheryavenko A.F., Anisimova V.A. Calcium-dependent mechanism of antiplatelet action of compound RU-891. Experimental and Clinical Pharmacology. - 2014. - Vol. 77. - No. 3. - pp. 16-19 (in Russian).
  13. Spasov A.A., Smirnov A.V., Kucheryavenko A.F. Antithrombotic activity of a new benzimidazole derivative on a model of thrombosis in mice. Bulletin of Experimental Biology and Medicine. - 2014. - Vol. 157. - No. 5. - pp. 595-598 (in Russian).
  14. Spasov A.A. et al. Antithrombotic activity of the compound RU-891. Experimental and Clinical Pharmacology. - 2013. - Vol. 76. - No. 6. - pp. 25-26 (in Russian).

补充文件

附件文件
动作
1. JATS XML

版权所有 © Spasov A.A., Kucheryavenko A.F., Maltsev D.V., Miroshnikov М.V., Sirotenko V.S., Sultanova К.Т., Gaidukova К.A., Skripka М.О., 2021



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.